Status:
NOT_YET_RECRUITING
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
Fifth Affiliated Hospital, Sun Yat-Sen University
Conditions:
Esophageal Cancer
Chemoradiotherapy
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory. More importantly, there is a lack of effectiv...
Eligibility Criteria
Inclusion
- Histologically confirmed squamous cell carcinoma of the esophagus;
- Locally advanced esophageal cancer classified as stage I-IVA (inoperable or patient declined surgery) or stage IVB thoracic esophageal cancer with supraclavicular lymph node metastasis only (AJCC 8th edition) prior to treatment;
- Completion of definitive concurrent chemoradiotherapy without disease progression; radiotherapy dose of 50-50.4 Gy using conventional fractionation and IMRT technique; concurrent platinum- or taxane-based doublet chemotherapy during radiotherapy; ≤4 cycles of induction chemotherapy allowed prior to radiotherapy; PD-1/PD-L1 antibody therapy permitted during induction chemotherapy and radiotherapy; no adjuvant therapy received;
- Enrollment window: within 1-42 days after completion of chemoradiotherapy;
- Age 18-75 years;
- Estimated life expectancy \>6 months;
- Eastern Cooperative Oncology Group performance status ≤ 2;
- The function of important organs meets the following requirements: a. white blood cell count (WBC) ≥3.5×109/L, absolute neutrophil count (ANC) ≥1.5×109/L; b. platelets ≥75×109/L; c. hemoglobin ≥9g/dL; d. serum albumin ≥2.8g/dL; e. total bilirubin ≤1.5×ULN, ALT, AST and/or AKP ≤2.5×ULN; f. serum creatinine ≤1.5×ULN or creatinine clearance rate \>60 mL/min;
- Ability to understand the trial details and has provided written informed consent.
Exclusion
- Patients who have received antitumor therapy (including adjuvant chemotherapy, surgery, immunotherapy, targeted therapy, etc.) after completion of chemoradiotherapy;
- Stage IVb patients with metastasis to solid organs (e.g., liver, bone, lung, brain, adrenal gland, peritoneum, etc.) at initial diagnosis;
- Known or suspected allergy to the investigational drug(s) or any agent related to the trial regimen;
- Presence of esophageal fistula and/or esophageal hemorrhage prior to enrollment;
- Disease progression after chemoradiotherapy;
- ≥Grade 2 radiation pneumonitis prior to enrollment;
- History of ≥ Grade 3 immune-related adverse events prior to enrollment;
- Prior treatment with targeted drugs;
- History of other malignant tumors besides esophageal cancer, except for non-melanoma skin cancer, carcinoma in situ of the cervix, papillary thyroid carcinoma, or cured early-stage prostate cancer;
- Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, hematopoietic system diseases, cachexia, or other conditions that make them unfit for chemotherapy;
- Female patients who are pregnant or breastfeeding;
- Inability to provide informed consent due to psychological, familial, social, or other factors;
- Presence of CTC grade ≥2 peripheral neuropathy;
- Patients with a history of diabetes for more than 10 years and poorly controlled blood glucose levels;
- History of autoimmune disease or autoimmune disorders (e.g., colitis, systemic lupus erythematosus, rheumatoid arthritis, uveitis, hypophysitis, hyperthyroidism; not limited to these diseases or syndromes), immunodeficiency history, including HIV positivity, or other acquired/congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation;
- History of interstitial lung disease or non-infectious pneumonia;
- Active hepatitis B (HBV DNA ≥2000 IU/mL or 10⁴ copies/mL) or hepatitis C (HCV antibody positive with HCV-RNA above the lower limit of detection);
- Any unstable condition that may jeopardize patient safety or compliance.
Key Trial Info
Start Date :
September 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2030
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT07177794
Start Date
September 20 2025
End Date
May 31 2030
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060